134 related articles for article (PubMed ID: 31171642)
1. Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.
Baas I; Delvasto-Nuñez L; Ligthart P; Brouwer C; Folman C; Reis ES; Ricklin D; Lambris JD; Wouters D; de Haas M; Jongerius I; Zeerleder SS
Haematologica; 2020; 105(2):e57-e60. PubMed ID: 31171642
[No Abstract] [Full Text] [Related]
2. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.
Risitano AM; Ricklin D; Huang Y; Reis ES; Chen H; Ricci P; Lin Z; Pascariello C; Raia M; Sica M; Del Vecchio L; Pane F; Lupu F; Notaro R; Resuello RR; DeAngelis RA; Lambris JD
Blood; 2014 Mar; 123(13):2094-101. PubMed ID: 24497537
[TBL] [Abstract][Full Text] [Related]
3. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy.
Zhang Y; Shao D; Ricklin D; Hilkin BM; Nester CM; Lambris JD; Smith RJ
Immunobiology; 2015 Aug; 220(8):993-8. PubMed ID: 25982307
[TBL] [Abstract][Full Text] [Related]
4. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.
Lindorfer MA; Cook EM; Reis ES; Ricklin D; Risitano AM; Lambris JD; Taylor RP
Clin Immunol; 2016 Oct; 171():32-35. PubMed ID: 27546448
[TBL] [Abstract][Full Text] [Related]
5. C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocycles.
Furlong ST; Dutta AS; Coath MM; Gormley JJ; Hubbs SJ; Lloyd D; Mauger RC; Strimpler AM; Sylvester MA; Scott CW; Edwards PD
Immunopharmacology; 2000 Jul; 48(2):199-212. PubMed ID: 10936517
[TBL] [Abstract][Full Text] [Related]
6. Safety profile after prolonged C3 inhibition.
Reis ES; Berger N; Wang X; Koutsogiannaki S; Doot RK; Gumas JT; Foukas PG; Resuello RRG; Tuplano JV; Kukis D; Tarantal AF; Young AJ; Kajikawa T; Soulika AM; Mastellos DC; Yancopoulou D; Biglarnia AR; Huber-Lang M; Hajishengallis G; Nilsson B; Lambris JD
Clin Immunol; 2018 Dec; 197():96-106. PubMed ID: 30217791
[TBL] [Abstract][Full Text] [Related]
7. Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood.
Abicht JM; Kourtzelis I; Reichart B; Koutsogiannaki S; Primikyri A; Lambris JD; Chavakis T; Holdt L; Kind A; Guethoff S; Mayr T
Xenotransplantation; 2017 Jan; 24(1):. PubMed ID: 27677785
[TBL] [Abstract][Full Text] [Related]
8. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3.
Soulika AM; Holland MC; Sfyroera G; Sahu A; Lambris JD
Mol Immunol; 2006 May; 43(12):2023-9. PubMed ID: 16472861
[TBL] [Abstract][Full Text] [Related]
9. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.
Lamers C; Xue X; Smieško M; van Son H; Wagner B; Berger N; Sfyroera G; Gros P; Lambris JD; Ricklin D
Nat Commun; 2022 Sep; 13(1):5519. PubMed ID: 36127336
[TBL] [Abstract][Full Text] [Related]
10. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC; Yancopoulou D; Kokkinos P; Huber-Lang M; Hajishengallis G; Biglarnia AR; Lupu F; Nilsson B; Risitano AM; Ricklin D; Lambris JD
Eur J Clin Invest; 2015 Apr; 45(4):423-40. PubMed ID: 25678219
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters.
Reis ES; DeAngelis RA; Chen H; Resuello RR; Ricklin D; Lambris JD
Immunobiology; 2015 Apr; 220(4):476-82. PubMed ID: 25468722
[TBL] [Abstract][Full Text] [Related]
12. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin.
Sahu A; Soulika AM; Morikis D; Spruce L; Moore WT; Lambris JD
J Immunol; 2000 Sep; 165(5):2491-9. PubMed ID: 10946275
[TBL] [Abstract][Full Text] [Related]
13. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40.
Wang J; Wang L; Xiang Y; Ricklin D; Lambris JD; Chen G
Clin Immunol; 2016 Jan; 162():37-44. PubMed ID: 26548839
[TBL] [Abstract][Full Text] [Related]
14. Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates.
Hughes S; Gumas J; Lee R; Rumano M; Berger N; Gautam AK; Sfyroera G; Chan AL; Gnanaguru G; Connor KM; Kim BJ; Dunaief JL; Ricklin D; Hajishengallis G; Yancopoulou D; Reis ES; Mastellos DC; Lambris JD
Clin Immunol; 2020 May; 214():108391. PubMed ID: 32229292
[TBL] [Abstract][Full Text] [Related]
15. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis.
Gullipalli D; Zhang F; Sato S; Ueda Y; Kimura Y; Golla M; Miwa T; Wang J; Song WC
J Immunol; 2018 Aug; 201(3):1021-1029. PubMed ID: 29898960
[TBL] [Abstract][Full Text] [Related]
16. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B; Larsson R; Hong J; Elgue G; Ekdahl KN; Sahu A; Lambris JD
Blood; 1998 Sep; 92(5):1661-7. PubMed ID: 9716594
[TBL] [Abstract][Full Text] [Related]
17. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
18. A new generation of potent complement inhibitors of the Compstatin family.
López de Victoria A; Gorham RD; Bellows-Peterson ML; Ling J; Lo DD; Floudas CA; Morikis D
Chem Biol Drug Des; 2011 Jun; 77(6):431-40. PubMed ID: 21352502
[TBL] [Abstract][Full Text] [Related]
19. In vitro Inhibition of Canine Complement-Mediated Hemolysis.
Hernandez DM; Goggs R; Behling-Kelly E
J Vet Intern Med; 2018 Jan; 32(1):142-146. PubMed ID: 29171101
[TBL] [Abstract][Full Text] [Related]
20. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
